Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters.
Delta
Omicron BA.1
SARS-CoV-2
Syrian golden hamster
pathology
pre-existing immunity
re-challenge
Journal
Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
pubmed:
6
7
2022
medline:
20
7
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
The Omicron BA.1 (B.1.1.529) SARS-CoV-2 variant is characterized by a high number of mutations in the viral genome, associated with immune escape and increased viral spread. It remains unclear whether milder COVID-19 disease progression observed after infection with Omicron BA.1 in humans is due to reduced pathogenicity of the virus or due to pre-existing immunity from vaccination or previous infection. Here, we inoculated hamsters with Omicron BA.1 to evaluate pathogenicity and kinetics of viral shedding, compared to Delta (B.1.617.2) and to animals re-challenged with Omicron BA.1 after previous SARS-CoV-2 614G infection. Omicron BA.1 infected animals showed reduced clinical signs, pathological changes, and viral shedding, compared to Delta-infected animals, but still showed gross- and histopathological evidence of pneumonia. Pre-existing immunity reduced viral shedding and protected against pneumonia. Our data indicate that the observed decrease of disease severity is in part due to intrinsic properties of the Omicron BA.1 variant.
Identifiants
pubmed: 35787236
doi: 10.1080/22221751.2022.2095932
pmc: PMC9295819
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1778-1786Références
Nature. 2021 Dec;600(7887):21
pubmed: 34824381
Elife. 2021 Apr 09;10:
pubmed: 33835028
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):
pubmed: 35058348
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
EBioMedicine. 2022 May;79:104008
pubmed: 35460989
Nature. 2022 Mar;603(7902):687-692
pubmed: 35062015
Cell Rep. 2022 Mar 15;38(11):110515
pubmed: 35263638
Cell Host Microbe. 2021 Apr 14;29(4):508-515
pubmed: 33789086
Int J Infect Dis. 2022 Jan;114:268-272
pubmed: 34863925
Elife. 2021 Jan 04;10:
pubmed: 33393462
J Chem Inf Model. 2022 Jan 24;62(2):412-422
pubmed: 34989238
J Genet Genomics. 2021 Dec;48(12):1111-1121
pubmed: 34954396
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Infect Dis. 2021 Jun 15;223(12):2020-2028
pubmed: 34043806
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Sci Immunol. 2022 Jun 23;:eabq4450
pubmed: 35737747
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Nat Rev Immunol. 2022 Feb;22(2):69-71
pubmed: 35046570
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Emerg Microbes Infect. 2020 Dec;9(1):837-842
pubmed: 32301390
Science. 2021 Mar 26;371(6536):1379-1382
pubmed: 33597220
Antiviral Res. 2022 Feb;198:105253
pubmed: 35066015
Nature. 2022 Jul;607(7917):119-127
pubmed: 35576972